Increased endothelin-1 responsiveness in human coronary artery smooth muscle cells exposed to 1, 25-dihydroxyvitamin D3

American Journal of Physiology - Cell Physiology

Volumn 304, Issue 7, 2013, Pages

  Absi, Mais ^a,b   Ward, Donald T ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF ALEPPO   (Syrian Arab Republic)

Author keywords

Coronary artery smooth muscle cells; Endothelin; Extracellular signal regulated kinase; Intra cellular calcium; Vitamin D3

Indexed keywords

CALCITRIOL; CALCIUM; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CALCIUM CELL LEVEL; CORONARY ARTERY SMOOTH MUSCLE CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; CELL CULTURE; CORONARY BLOOD VESSEL; CYTOLOGY; DRUG EFFECT; GENETICS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CALCITRIOL; CALCIUM; CELLS, CULTURED; CORONARY VESSELS; ENDOTHELIN-1; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; RECEPTORS, ENDOTHELIN; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84878250816     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00349.2012     Document Type: Article

References (33)

1. Adams JS, Hewison M. Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. Arch Biochem Biophys 523: 95-102, 2012.
2. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 10: 1730-1737, 2007.
3. Bkaily G, Avedanian L, Al-Khoury J, Provost C, Nader M, D'Orléans-Juste P, Jacques D. Nuclear membrane receptors for ET-1 in cardiovascular function. Am J Physiol Regul Integr Comp Physiol 300: R251-R263, 2011.
4. Chen S, Law CS, Gardner DG. Vitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity. J Steroid Biochem Mol Biol 118: 135-141, 2010.
5. Clozel M, Gray GA, Breu V, Loffler BM, Osterwalker R. The endo-thelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 186: 867-873, 1992.
6. Compeer MG, Meens MJ, Hackeng TM, Neugebauer WA, Höltke C, De Mey JG. Agonist-dependent modulation of arterial endothelin A receptor function. Br J Pharmacol 166: 1833-1845, 2012.
7. Cunningham J, Zehnder D. New vitamin D analogs and changing therapeutic paradigms. Kidney Int 79: 702-707, 2011.
8. Dai X, Galligan JJ. Expressed in HEK 293 cells differential trafficking and desensitization of human ETA and ETB receptors. Exp Biol Med (Maywood) 231: 746-751, 2006.
9. Gregan B, Jurgensen J, Papsdorf G, Furkert J, Schaefer M, Beyer-mann M, Rosenthal W, Oksche A. Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem 279: 27679-27687, 2004.
10. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16: 1081-1098, 1998.
11. Holick MF. Vitamin D deficiency. N Engl J Med 357: 266-281, 2007.
12. Jones G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha, 25-dihydroxyvitamin D(3). Semin Dial 20: 316-324, 2007.
13. Judd SE, Tangpricha V. Vitamin D deficiency and risk for cardiovas-cular disease. Am J Med Sci 338: 40-44, 2009.
14. Khimji AK, Rockey DC. Endothelin-biology and disease. Cell Signal 22: 1615-1625, 2010.
15. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency: an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 52: 1949-1956, 2008.
16. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, Felsenfeld A, Levine B, Mehrotra R, Norris K. Prevalence of cardio-vascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Exam-ination Survey. Arch Intern Med 167: 1159-1165, 2007.
17. Merke J, Milde P, Lewicka S, Hugel U, Klaus G, Mangelsdorf DJ, Haussler MR, Rauterberg EW, Ritz E. Identification and regulation of 1, 25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1, 25-dihydroxyvitamin. J Clin Invest 83: 1903-1915, 1989.
18. Nambi P, Wu HL, Lipshutz D, Prabhakar U. Identification and char-acterization of endothelin receptors on rat osteoblastic osteosarcoma cells: down-regulation by 1, 25-dihydroxy-vitamin D3. Mol Pharmacol 47: 266-271, 1995.
19. Oghlakian G, Klapholz M. Vasopressin and vasopressin receptor antag-onists in heart failure. Cardiol Rev 17: 10-15, 2009.
20. Rodríguez-Pascual F, Busnadiego O, Lagares D, Lamas S. Role of endothelin in the cardiovascular system. Pharmacol Res 63: 463-472, 2011.
21. Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci 13: 103-108, 1992.
22. Shapses SA, Manson JE. Vitamin D and prevention of cardiovascular disease and diabetes: why the evidence falls short. JAMA 305: 2565-2566, 2011.
23. Shroff R, Egerton M, Bridel M, Shah V, Donald AE, Cole TJ, Hiorns MP, Deanfield JE, Rees L. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 19: 1239-1246, 2008.
24. Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, Jaccard N, Knoll E, Stern N. 25-Hydroxyvitamin D3-1alpha-hydroxy-lase is expressed in human vascular smooth muscle cells and is upregu-lated by parathyroid hormone and estrogenic compounds. Circulation 111: 1666-1671, 2005.
25. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307: 674-684, 2012.
26. Walch L, Brink C, Norel X. The muscarinic receptor subtypes in human blood vessels. Therapie 56: 223-226, 2001.
27. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117: 503-511, 2008.
28. Ward DT, Brown EM, Harris HW. Disulfide bonds in the extracellular calcium-polyvalent cation-sensing receptor correlate with dimer forma-tion, and its response to divalent cations in vitro. J Biol Chem 273: 14476-14483, 1998.
29. Webster BR, Osmond JM, Paredes DA, Deleon XA, Jackson-Weaver O, Walker BR, Kanagy NL. Phosphoinositide-dependent kinase-1 and protein kinase cδ contribute to endothelin-1 constriction and elevated blood pressure in intermittent hypoxia. J Pharmacol Exp Ther 344: 68-76, 2013.
30. Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger PE. VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. J Cell Biochem 100: 1395-1405, 2007.
31. Wu-Wong JR. Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. Br J Pharmacol 158: 395-412, 2009.
32. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.
33. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, Stewart PM, Hewison M. Synthesis of 1, 25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 13: 621-629, 2002.